JP2010500994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500994A5 JP2010500994A5 JP2009524671A JP2009524671A JP2010500994A5 JP 2010500994 A5 JP2010500994 A5 JP 2010500994A5 JP 2009524671 A JP2009524671 A JP 2009524671A JP 2009524671 A JP2009524671 A JP 2009524671A JP 2010500994 A5 JP2010500994 A5 JP 2010500994A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- phenyl
- methyloxy
- sulfonyl
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 16
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims description 15
- 108091007960 PI3Ks Proteins 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 695
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 358
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 353
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 338
- -1 lower alkanyl Chemical group 0.000 claims 152
- 125000001072 heteroaryl group Chemical group 0.000 claims 46
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 43
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 125000001475 halogen functional group Chemical group 0.000 claims 34
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 33
- 229910052739 hydrogen Inorganic materials 0.000 claims 33
- 239000001257 hydrogen Substances 0.000 claims 33
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 28
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims 22
- 125000003342 alkenyl group Chemical group 0.000 claims 21
- 125000003107 substituted aryl group Chemical group 0.000 claims 21
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 19
- 150000002431 hydrogen Chemical class 0.000 claims 19
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 18
- 125000001188 haloalkyl group Chemical group 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 16
- 125000000304 alkynyl group Chemical group 0.000 claims 15
- 150000001408 amides Chemical class 0.000 claims 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 15
- 125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 125000004438 haloalkoxy group Chemical group 0.000 claims 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 9
- 241001024304 Mino Species 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 8
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 7
- 229940124530 sulfonamide Drugs 0.000 claims 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 4
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 150000003456 sulfonamides Chemical class 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 3
- VALZSZJVEFACEZ-UHFFFAOYSA-N azetidine-3-carboxamide Chemical compound NC(=O)C1CNC1 VALZSZJVEFACEZ-UHFFFAOYSA-N 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 3
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- IRHDSXMLSTVXEQ-UHFFFAOYSA-N 2-(ethylamino)-4-methyl-8-propan-2-yl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C(C)C)C2=NC(NCC)=NC(C)=C2C=C1C=1C=CNN=1 IRHDSXMLSTVXEQ-UHFFFAOYSA-N 0.000 claims 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 2
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 2
- HAKUWOSPROHOHW-UHFFFAOYSA-N 8-cyclopentyl-2-(ethylamino)-4-methyl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C2CCCC2)C2=NC(NCC)=NC(C)=C2C=C1C=1C=CNN=1 HAKUWOSPROHOHW-UHFFFAOYSA-N 0.000 claims 2
- HIHMKBKMKSYHII-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=CC=C1 HIHMKBKMKSYHII-UHFFFAOYSA-N 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 229910002651 NO3 Inorganic materials 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000004965 chloroalkyl group Chemical group 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- IADUEWIQBXOCDZ-UHFFFAOYSA-N (2S)-azetidine-2-carboxylic acid Natural products OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 claims 1
- DBTDBYINUJMLRZ-UHFFFAOYSA-N (3,3-difluoroazetidin-1-yl)-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]methanone Chemical compound C=1C=C(I)C=C(F)C=1NC1=C(F)C(F)=CC=C1C(=O)N1CC(F)(F)C1 DBTDBYINUJMLRZ-UHFFFAOYSA-N 0.000 claims 1
- AMKMWZPNFOTRDH-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]methanone Chemical compound C1C(N)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F AMKMWZPNFOTRDH-UHFFFAOYSA-N 0.000 claims 1
- ZZJMLFCTJLGTEI-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[4-(2-fluoro-4-iodoanilino)thiophen-3-yl]methanone Chemical compound C1C(N)CN1C(=O)C1=CSC=C1NC1=CC=C(I)C=C1F ZZJMLFCTJLGTEI-UHFFFAOYSA-N 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- DSIBSRXKQRYPJP-UHFFFAOYSA-N 1,2-oxazole-5-carboxamide Chemical compound NC(=O)C1=CC=NO1 DSIBSRXKQRYPJP-UHFFFAOYSA-N 0.000 claims 1
- OIEUKOXYYRCJOB-UHFFFAOYSA-N 1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-n-hydroxyazetidine-2-carboxamide Chemical compound ONC(=O)C1CCN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F OIEUKOXYYRCJOB-UHFFFAOYSA-N 0.000 claims 1
- VGQZTOCHLVGGBK-UHFFFAOYSA-N 1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-n-hydroxyazetidine-3-carboxamide Chemical compound C1C(C(=O)NO)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F VGQZTOCHLVGGBK-UHFFFAOYSA-N 0.000 claims 1
- UJXSKQZZTUMIPR-UHFFFAOYSA-N 1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-n-methyl-n-prop-2-enylazetidine-3-carboxamide Chemical compound C1C(C(=O)N(CC=C)C)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F UJXSKQZZTUMIPR-UHFFFAOYSA-N 0.000 claims 1
- OUZFPOWROZRFOA-UHFFFAOYSA-N 1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-n-methylazetidine-3-carboxamide Chemical compound C1C(C(=O)NC)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F OUZFPOWROZRFOA-UHFFFAOYSA-N 0.000 claims 1
- JNRJARCELIUHEU-UHFFFAOYSA-N 1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]azetidin-3-one Chemical compound C=1C=C(I)C=C(F)C=1NC1=C(F)C(F)=CC=C1C(=O)N1CC(=O)C1 JNRJARCELIUHEU-UHFFFAOYSA-N 0.000 claims 1
- QYQLVTVZLMBZKM-UHFFFAOYSA-N 1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]azetidine-2-carboxylic acid Chemical compound OC(=O)C1CCN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F QYQLVTVZLMBZKM-UHFFFAOYSA-N 0.000 claims 1
- KDMCTGAOBPQHRZ-UHFFFAOYSA-N 1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]azetidine-3-carboxylic acid Chemical compound C1C(C(=O)O)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F KDMCTGAOBPQHRZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004486 1-methylpiperidin-3-yl group Chemical group CN1CC(CCC1)* 0.000 claims 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- HTJOVUNXGJONIS-UHFFFAOYSA-N 2-(benzylamino)-6-bromo-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NCC1=CC=CC=C1 HTJOVUNXGJONIS-UHFFFAOYSA-N 0.000 claims 1
- JMNLUUPZYOLBHN-UHFFFAOYSA-N 2-(ethylamino)-4-methyl-6-(1H-pyrazol-5-yl)-8H-pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1NC2=NC(NCC)=NC(C)=C2C=C1C=1C=CNN=1 JMNLUUPZYOLBHN-UHFFFAOYSA-N 0.000 claims 1
- ZHRYNYKDUYSRGB-UHFFFAOYSA-N 2-(ethylamino)-4-methyl-8-propan-2-yl-6-pyrazol-1-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C(C)C)C2=NC(NCC)=NC(C)=C2C=C1N1C=CC=N1 ZHRYNYKDUYSRGB-UHFFFAOYSA-N 0.000 claims 1
- HSEBQNPXSICMIB-UHFFFAOYSA-N 2-(ethylamino)-4-methyl-8-propan-2-yl-6-thiophen-2-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C(C)C)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=CS1 HSEBQNPXSICMIB-UHFFFAOYSA-N 0.000 claims 1
- QRJXSWSAFBXPGH-UHFFFAOYSA-N 2-(ethylamino)-6-(furan-3-yl)-4-methyl-8-propan-2-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C(C)C)C2=NC(NCC)=NC(C)=C2C=C1C=1C=COC=1 QRJXSWSAFBXPGH-UHFFFAOYSA-N 0.000 claims 1
- CBBFWSMELCDMPZ-UHFFFAOYSA-N 2-(methylamino)acetamide Chemical compound CNCC(N)=O CBBFWSMELCDMPZ-UHFFFAOYSA-N 0.000 claims 1
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 claims 1
- GWQBQZWHKVNWAQ-UHFFFAOYSA-N 2-[4-(4-benzylpiperazin-1-yl)anilino]-6-bromo-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1 GWQBQZWHKVNWAQ-UHFFFAOYSA-N 0.000 claims 1
- AAZQBTDBIDQFOT-UHFFFAOYSA-N 2-[4-(4-benzylpiperazin-1-yl)anilino]-8-ethyl-4-methyl-6-thiophen-2-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(C=3SC=CC=3)C(=O)N(CC)C2=NC=1NC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1 AAZQBTDBIDQFOT-UHFFFAOYSA-N 0.000 claims 1
- FPWGZOOQOSVFNF-UHFFFAOYSA-N 2-[4-(4-ethylpiperazin-1-yl)anilino]-4-methyl-6-phenyl-8-propan-2-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(C=2C=CC=CC=2)C(=O)N2C(C)C)C2=N1 FPWGZOOQOSVFNF-UHFFFAOYSA-N 0.000 claims 1
- GXWZBYLDKUHYMM-UHFFFAOYSA-N 2-[4-(4-ethylpiperazin-1-yl)anilino]-4-methyl-8-propan-2-yl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(C2=NNC=C2)C(=O)N2C(C)C)C2=N1 GXWZBYLDKUHYMM-UHFFFAOYSA-N 0.000 claims 1
- FMKRGZMYBBIDRU-UHFFFAOYSA-N 2-[4-(4-ethylpiperazin-1-yl)anilino]-4-methyl-8-propan-2-yl-6-pyrazol-1-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(N2N=CC=C2)C(=O)N2C(C)C)C2=N1 FMKRGZMYBBIDRU-UHFFFAOYSA-N 0.000 claims 1
- LCQNZXBWUQGXRT-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-8-ethyl-4-methyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC(C)=C(C=C(C=2C=CC=CC=2)C(=O)N2CC)C2=N1 LCQNZXBWUQGXRT-UHFFFAOYSA-N 0.000 claims 1
- HZRBHCGEYZORAK-UHFFFAOYSA-N 2-amino-4-methyl-8-propan-2-yl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C(C)C)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 HZRBHCGEYZORAK-UHFFFAOYSA-N 0.000 claims 1
- QSWPHEWUFGXYPX-UHFFFAOYSA-N 2-amino-8-cyclopentyl-4-methyl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1C(C2=NNC=C2)=CC=2C(C)=NC(N)=NC=2N1C1CCCC1 QSWPHEWUFGXYPX-UHFFFAOYSA-N 0.000 claims 1
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- PCVGVJIERNKFME-UHFFFAOYSA-N 2-anilino-6-bromo-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NC1=CC=CC=C1 PCVGVJIERNKFME-UHFFFAOYSA-N 0.000 claims 1
- ZSBCYLLGJGQANG-UHFFFAOYSA-N 2-anilino-8-cyclopentyl-4-methyl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C=2N(C3CCCC3)C(=O)C(C3=NNC=C3)=CC=2C(C)=NC=1NC1=CC=CC=C1 ZSBCYLLGJGQANG-UHFFFAOYSA-N 0.000 claims 1
- VWDQGKGGOXAPIQ-UHFFFAOYSA-N 2-anilino-8-ethyl-4-methyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(C=3C=CC=CC=3)C(=O)N(CC)C2=NC=1NC1=CC=CC=C1 VWDQGKGGOXAPIQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- XOPHSIJCGCQZOK-UHFFFAOYSA-N 3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]-n-methyl-n-propylbenzamide Chemical compound CCCN(C)C(=O)C1=CC=CC(S(=O)(=O)NC=2C(=NC3=CC=CC=C3N=2)NC=2C(=CC=C(OC)C=2)Cl)=C1 XOPHSIJCGCQZOK-UHFFFAOYSA-N 0.000 claims 1
- QOTWUKYEVXQWJJ-UHFFFAOYSA-N 3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(S(=O)(=O)NC=2C(=NC3=CC=CC=C3N=2)NC=2C(=CC=C(OC)C=2)Cl)=C1 QOTWUKYEVXQWJJ-UHFFFAOYSA-N 0.000 claims 1
- KDLLXOWUFSLOLC-UHFFFAOYSA-N 3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]-n-morpholin-4-ylbenzamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)C(=O)NN2CCOCC2)=C1 KDLLXOWUFSLOLC-UHFFFAOYSA-N 0.000 claims 1
- HKRRWBZVMIBYNZ-UHFFFAOYSA-N 3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]-n-piperidin-1-ylbenzamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)C(=O)NN2CCCCC2)=C1 HKRRWBZVMIBYNZ-UHFFFAOYSA-N 0.000 claims 1
- XWRPSZLAKYJPJI-UHFFFAOYSA-N 3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]-n-piperidin-3-ylbenzamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)C(=O)NC2CNCCC2)=C1 XWRPSZLAKYJPJI-UHFFFAOYSA-N 0.000 claims 1
- OEBUKKCBNNDZOY-UHFFFAOYSA-N 3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]-n-pyrrol-1-ylbenzamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)C(=O)NN2C=CC=C2)=C1 OEBUKKCBNNDZOY-UHFFFAOYSA-N 0.000 claims 1
- SQKFHPRIYPTURG-UHFFFAOYSA-N 3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]-n-pyrrolidin-3-ylbenzamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)C(=O)NC2CNCC2)=C1 SQKFHPRIYPTURG-UHFFFAOYSA-N 0.000 claims 1
- JDZWNQFNSIMKDH-UHFFFAOYSA-N 3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]benzoic acid Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)C(O)=O)=C1 JDZWNQFNSIMKDH-UHFFFAOYSA-N 0.000 claims 1
- ILNSWQIMAIJVQE-UHFFFAOYSA-N 3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]benzoic acid Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)C(O)=O)=C1 ILNSWQIMAIJVQE-UHFFFAOYSA-N 0.000 claims 1
- FIWLKIGWOPEVCT-UHFFFAOYSA-N 3-nitro-n-[3-(1h-pyrazolo[3,4-d]pyrimidin-4-ylamino)quinoxalin-2-yl]benzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC=2C(=NC3=CC=CC=C3N=2)NC=2C=3C=NNC=3N=CN=2)=C1 FIWLKIGWOPEVCT-UHFFFAOYSA-N 0.000 claims 1
- XPJLKNOITRUOGB-UHFFFAOYSA-N 3-nitro-n-[3-(3-propan-2-yloxyanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound CC(C)OC1=CC=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 XPJLKNOITRUOGB-UHFFFAOYSA-N 0.000 claims 1
- SZAWPKBBEKWTKA-UHFFFAOYSA-N 4-chloro-n-[3-(2,5-dimethoxyanilino)pyrazin-2-yl]benzenesulfonamide Chemical compound COC1=CC=C(OC)C(NC=2C(=NC=CN=2)NS(=O)(=O)C=2C=CC(Cl)=CC=2)=C1 SZAWPKBBEKWTKA-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- JVFCCRJSBNUDDU-UHFFFAOYSA-N 4-phenylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=CC=CC=C1 JVFCCRJSBNUDDU-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- BCDRQSSWCXRYNO-UHFFFAOYSA-N 5-cyclopentyl-2-[4-(4-ethylpiperazin-1-yl)anilino]-4-methyl-6-(1H-pyrazol-5-yl)-8H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C(C2CCCC2)=C(C=2NN=CC=2)C(=O)N2)C2=N1 BCDRQSSWCXRYNO-UHFFFAOYSA-N 0.000 claims 1
- LIFZCUXXZQSXLK-UHFFFAOYSA-N 6-(1-benzylpyrazol-4-yl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C(=C1)C=NN1CC1=CC=CC=C1 LIFZCUXXZQSXLK-UHFFFAOYSA-N 0.000 claims 1
- TYMVEOHFGMXJPE-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=C(Cl)C=C1Cl TYMVEOHFGMXJPE-UHFFFAOYSA-N 0.000 claims 1
- YAYKCZVICGUZSA-UHFFFAOYSA-N 6-(2,4-difluorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=C(F)C=C1F YAYKCZVICGUZSA-UHFFFAOYSA-N 0.000 claims 1
- VKBJZQDLVWHJPO-UHFFFAOYSA-N 6-(2,4-dimethoxyphenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=C(OC)C=C1OC VKBJZQDLVWHJPO-UHFFFAOYSA-N 0.000 claims 1
- PWDHNKMEIRYSOQ-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=C(F)C(F)=C1 PWDHNKMEIRYSOQ-UHFFFAOYSA-N 0.000 claims 1
- NRBMCGYSVZEPIU-UHFFFAOYSA-N 6-(3,5-dimethyl-1,2-oxazol-4-yl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C=1C(C)=NOC=1C NRBMCGYSVZEPIU-UHFFFAOYSA-N 0.000 claims 1
- VDXQMPQWMPWTDH-UHFFFAOYSA-N 6-(3-chloro-4-fluorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=C(F)C(Cl)=C1 VDXQMPQWMPWTDH-UHFFFAOYSA-N 0.000 claims 1
- QYOALVAEYOXRPS-UHFFFAOYSA-N 6-(3-chlorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=CC(Cl)=C1 QYOALVAEYOXRPS-UHFFFAOYSA-N 0.000 claims 1
- OHNOBNXTECPTTL-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=C(Cl)C=C1 OHNOBNXTECPTTL-UHFFFAOYSA-N 0.000 claims 1
- DGRRKSNJOVHVFZ-UHFFFAOYSA-N 6-(5-chlorothiophen-2-yl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=C(Cl)S1 DGRRKSNJOVHVFZ-UHFFFAOYSA-N 0.000 claims 1
- KBYOZBZPCUHZRD-UHFFFAOYSA-N 6-acetyl-8-ethyl-2-[4-(4-ethylpiperazin-1-yl)anilino]-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(C(C)=O)C(=O)N2CC)C2=N1 KBYOZBZPCUHZRD-UHFFFAOYSA-N 0.000 claims 1
- GUXQXARJIPRGEG-UHFFFAOYSA-N 6-bromo-2-(cyclohexylamino)-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NC1CCCCC1 GUXQXARJIPRGEG-UHFFFAOYSA-N 0.000 claims 1
- AIELSQNLZXOUOU-UHFFFAOYSA-N 6-bromo-2-(cyclopentylamino)-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NC1CCCC1 AIELSQNLZXOUOU-UHFFFAOYSA-N 0.000 claims 1
- YYUQBZSKMAVNRJ-UHFFFAOYSA-N 6-bromo-2-(ethylamino)-4-methyl-8-(2-piperidin-1-ylethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NCC)=NC(C)=C2C=C(Br)C(=O)N1CCN1CCCCC1 YYUQBZSKMAVNRJ-UHFFFAOYSA-N 0.000 claims 1
- LMLIISHGMOULFX-UHFFFAOYSA-N 6-bromo-2-(ethylamino)-4-methyl-8-(3-propan-2-yloxypropyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C(Br)C(=O)N(CCCOC(C)C)C2=NC(NCC)=NC(C)=C21 LMLIISHGMOULFX-UHFFFAOYSA-N 0.000 claims 1
- UWCMJDGQKFCZEC-UHFFFAOYSA-N 6-bromo-2-(ethylamino)-4-methyl-8-propan-2-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C(Br)C(=O)N(C(C)C)C2=NC(NCC)=NC(C)=C21 UWCMJDGQKFCZEC-UHFFFAOYSA-N 0.000 claims 1
- BXAJJVRCDSJZLA-UHFFFAOYSA-N 6-bromo-2-(ethylamino)-8-(2-hydroxyethyl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C(Br)C(=O)N(CCO)C2=NC(NCC)=NC(C)=C21 BXAJJVRCDSJZLA-UHFFFAOYSA-N 0.000 claims 1
- DQIRWIFIZJQMAD-UHFFFAOYSA-N 6-bromo-2-(ethylamino)-8-(3-hydroxypropyl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C(Br)C(=O)N(CCCO)C2=NC(NCC)=NC(C)=C21 DQIRWIFIZJQMAD-UHFFFAOYSA-N 0.000 claims 1
- LWKXCJSJZISLME-UHFFFAOYSA-N 6-bromo-2-(ethylamino)-8-(3-methoxypropyl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C(Br)C(=O)N(CCCOC)C2=NC(NCC)=NC(C)=C21 LWKXCJSJZISLME-UHFFFAOYSA-N 0.000 claims 1
- XJXIMYBBBLWAOU-UHFFFAOYSA-N 6-bromo-2-(tert-butylamino)-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound CC(C)(C)NC1=NC(C)=C2C=C(Br)C(=O)N(CC)C2=N1 XJXIMYBBBLWAOU-UHFFFAOYSA-N 0.000 claims 1
- CJUKHJHPCSVISQ-UHFFFAOYSA-N 6-bromo-2-[3-(dimethylamino)propylamino]-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound CN(C)CCCNC1=NC(C)=C2C=C(Br)C(=O)N(CC)C2=N1 CJUKHJHPCSVISQ-UHFFFAOYSA-N 0.000 claims 1
- NIQVMNKCATXZOP-UHFFFAOYSA-N 6-bromo-2-[4-(4-ethylpiperazin-1-yl)anilino]-4-methyl-8-propan-2-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(Br)C(=O)N2C(C)C)C2=N1 NIQVMNKCATXZOP-UHFFFAOYSA-N 0.000 claims 1
- LNWTXVBBJHOKOI-UHFFFAOYSA-N 6-bromo-8-(2-ethoxyethyl)-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C(Br)C(=O)N(CCOCC)C2=NC(NCC)=NC(C)=C21 LNWTXVBBJHOKOI-UHFFFAOYSA-N 0.000 claims 1
- MOVZKOKKSKWSEX-UHFFFAOYSA-N 6-bromo-8-(3-ethoxypropyl)-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C(Br)C(=O)N(CCCOCC)C2=NC(NCC)=NC(C)=C21 MOVZKOKKSKWSEX-UHFFFAOYSA-N 0.000 claims 1
- NXAJMDSKXCTDLZ-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-(4-hydroxyanilino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C=2N(C3CCCC3)C(=O)C(Br)=CC=2C(C)=NC=1NC1=CC=C(O)C=C1 NXAJMDSKXCTDLZ-UHFFFAOYSA-N 0.000 claims 1
- VMPXUVSZWDXYOJ-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NCC)=NC(C)=C2C=C(Br)C(=O)N1C1CCCC1 VMPXUVSZWDXYOJ-UHFFFAOYSA-N 0.000 claims 1
- KXEVUKRKAURYLW-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-4-methyl-2-[4-(2-piperidin-1-ylethoxy)anilino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C=2N(C3CCCC3)C(=O)C(Br)=CC=2C(C)=NC=1NC(C=C1)=CC=C1OCCN1CCCCC1 KXEVUKRKAURYLW-UHFFFAOYSA-N 0.000 claims 1
- LEYMVVQOTDQCJY-UHFFFAOYSA-N 6-bromo-8-cyclopropyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NCC)=NC(C)=C2C=C(Br)C(=O)N1C1CC1 LEYMVVQOTDQCJY-UHFFFAOYSA-N 0.000 claims 1
- MLDPYVPXEDGNCE-UHFFFAOYSA-N 6-bromo-8-ethyl-2-(2-fluoroanilino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NC1=CC=CC=C1F MLDPYVPXEDGNCE-UHFFFAOYSA-N 0.000 claims 1
- JRWPTNNXOLYHTL-UHFFFAOYSA-N 6-bromo-8-ethyl-2-(4-fluoroanilino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NC1=CC=C(F)C=C1 JRWPTNNXOLYHTL-UHFFFAOYSA-N 0.000 claims 1
- ANZAZFFINQEQTC-UHFFFAOYSA-N 6-bromo-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C(Br)C(=O)N(CC)C2=NC(NCC)=NC(C)=C21 ANZAZFFINQEQTC-UHFFFAOYSA-N 0.000 claims 1
- NFAIYTSZZXYUDB-UHFFFAOYSA-N 6-bromo-8-ethyl-2-[4-(4-ethylpiperazin-1-yl)anilino]-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(Br)C(=O)N2CC)C2=N1 NFAIYTSZZXYUDB-UHFFFAOYSA-N 0.000 claims 1
- SIWZOCORNHHBFC-UHFFFAOYSA-N 6-bromo-8-ethyl-4-methyl-2-(2-morpholin-4-ylethylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NCCN1CCOCC1 SIWZOCORNHHBFC-UHFFFAOYSA-N 0.000 claims 1
- LOBJRYLVEQDBPO-UHFFFAOYSA-N 6-bromo-8-ethyl-4-methyl-2-(3-morpholin-4-ylpropylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NCCCN1CCOCC1 LOBJRYLVEQDBPO-UHFFFAOYSA-N 0.000 claims 1
- BUJJXZZBSTYLJG-UHFFFAOYSA-N 6-bromo-8-ethyl-4-methyl-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NC(C=C1)=CC=C1N1CCOCC1 BUJJXZZBSTYLJG-UHFFFAOYSA-N 0.000 claims 1
- FNGKJSWZQZYERI-UHFFFAOYSA-N 6-bromo-8-ethyl-4-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NC(C=C1)=CC=C1N1CCNCC1 FNGKJSWZQZYERI-UHFFFAOYSA-N 0.000 claims 1
- KTXZOODLBVKJKM-UHFFFAOYSA-N 6-bromo-8-ethyl-4-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound CNC1=NC(C)=C2C=C(Br)C(=O)N(CC)C2=N1 KTXZOODLBVKJKM-UHFFFAOYSA-N 0.000 claims 1
- SQQXWZWPSPKXOU-UHFFFAOYSA-N 6-bromo-8-ethyl-4-methyl-2-(propan-2-ylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound CC(C)NC1=NC(C)=C2C=C(Br)C(=O)N(CC)C2=N1 SQQXWZWPSPKXOU-UHFFFAOYSA-N 0.000 claims 1
- DQXTYECQBMLSLO-UHFFFAOYSA-N 6-bromo-8-ethyl-4-methyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(Br)C(=O)N(CC)C2=NC=1NC(C=C1)=CC=C1N1CCN(C)CC1 DQXTYECQBMLSLO-UHFFFAOYSA-N 0.000 claims 1
- XMEZKAIELOKSNK-UHFFFAOYSA-N 8-cyclohexyl-2-(ethylamino)-4-methyl-6-thiophen-2-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C2CCCCC2)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=CS1 XMEZKAIELOKSNK-UHFFFAOYSA-N 0.000 claims 1
- SIVGQKWCODHFNW-UHFFFAOYSA-N 8-cyclopentyl-2-(4-fluoroanilino)-4-methyl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C=2N(C3CCCC3)C(=O)C(C3=NNC=C3)=CC=2C(C)=NC=1NC1=CC=C(F)C=C1 SIVGQKWCODHFNW-UHFFFAOYSA-N 0.000 claims 1
- YELSUCDKJBIDHK-UHFFFAOYSA-N 8-cyclopentyl-2-(ethylamino)-4-methyl-6-pyrazol-1-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C2CCCC2)C2=NC(NCC)=NC(C)=C2C=C1N1C=CC=N1 YELSUCDKJBIDHK-UHFFFAOYSA-N 0.000 claims 1
- KIHITVHQQZKMCT-UHFFFAOYSA-N 8-cyclopentyl-2-[4-(4-ethylpiperazin-1-yl)anilino]-4-methyl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(C2=NNC=C2)C(=O)N2C3CCCC3)C2=N1 KIHITVHQQZKMCT-UHFFFAOYSA-N 0.000 claims 1
- VGVVGLZITQKFOW-UHFFFAOYSA-N 8-cyclopentyl-2-[4-(4-ethylpiperazin-1-yl)anilino]-4-methyl-6-pyrazol-1-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(N2N=CC=C2)C(=O)N2C3CCCC3)C2=N1 VGVVGLZITQKFOW-UHFFFAOYSA-N 0.000 claims 1
- UDTYZFNSBPJGPA-UHFFFAOYSA-N 8-cyclopentyl-4-methyl-2-(4-piperazin-1-ylanilino)-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C=2N(C3CCCC3)C(=O)C(C=3NN=CC=3)=CC=2C(C)=NC=1NC(C=C1)=CC=C1N1CCNCC1 UDTYZFNSBPJGPA-UHFFFAOYSA-N 0.000 claims 1
- QJPJYBSSDNQQRU-UHFFFAOYSA-N 8-ethyl-2-(2-fluoroethylamino)-4-methyl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCCF)=NC(C)=C2C=C1C1=CC=NN1 QJPJYBSSDNQQRU-UHFFFAOYSA-N 0.000 claims 1
- PQOSBVKEVAJMTP-UHFFFAOYSA-N 8-ethyl-2-(4-hydroxyanilino)-4-methyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(C=3C=CC=CC=3)C(=O)N(CC)C2=NC=1NC1=CC=C(O)C=C1 PQOSBVKEVAJMTP-UHFFFAOYSA-N 0.000 claims 1
- XEIHFSVZTFDIGS-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-(1,3-thiazol-2-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=NC=CS1 XEIHFSVZTFDIGS-UHFFFAOYSA-N 0.000 claims 1
- YJMFDEYHLMFOSN-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=NN1 YJMFDEYHLMFOSN-UHFFFAOYSA-N 0.000 claims 1
- BEPVPUYZYQRJAQ-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-(1h-pyrrol-2-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=CN1 BEPVPUYZYQRJAQ-UHFFFAOYSA-N 0.000 claims 1
- NLRSTBWELKXVHN-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-(4-methylthiophen-2-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC(C)=CS1 NLRSTBWELKXVHN-UHFFFAOYSA-N 0.000 claims 1
- XFVJUMGGCIFZBT-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-(4-methylthiophen-3-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CSC=C1C XFVJUMGGCIFZBT-UHFFFAOYSA-N 0.000 claims 1
- YZMVDDBAGFMGBA-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-(4-phenoxyphenyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 YZMVDDBAGFMGBA-UHFFFAOYSA-N 0.000 claims 1
- CJJJBJIUWTYIAY-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-(4-phenylphenyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C(C=C1)=CC=C1C1=CC=CC=C1 CJJJBJIUWTYIAY-UHFFFAOYSA-N 0.000 claims 1
- WOQNWAFKWIBAFO-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-(5-phenylthiophen-2-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C(S1)=CC=C1C1=CC=CC=C1 WOQNWAFKWIBAFO-UHFFFAOYSA-N 0.000 claims 1
- MBDJOCGVQVXRTP-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-[3-(trifluoromethyl)phenyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=CC(C(F)(F)F)=C1 MBDJOCGVQVXRTP-UHFFFAOYSA-N 0.000 claims 1
- CSPSPXHFDYRQAI-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-pyrazol-1-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1N1C=CC=N1 CSPSPXHFDYRQAI-UHFFFAOYSA-N 0.000 claims 1
- UGWQQIPKTBUFRP-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-pyrimidin-5-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CN=CN=C1 UGWQQIPKTBUFRP-UHFFFAOYSA-N 0.000 claims 1
- IYROWIUMRWBPSD-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-thiophen-2-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=CS1 IYROWIUMRWBPSD-UHFFFAOYSA-N 0.000 claims 1
- UCNWJNJPCDCHIR-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-4-methyl-6-thiophen-3-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C=1C=CSC=1 UCNWJNJPCDCHIR-UHFFFAOYSA-N 0.000 claims 1
- HIGCMWPMIDVKLQ-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-6-(1h-indol-6-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C2C=CNC2=CC(C2=CC3=C(C)N=C(N=C3N(CC)C2=O)NCC)=C1 HIGCMWPMIDVKLQ-UHFFFAOYSA-N 0.000 claims 1
- IATKCZGRJQMHGD-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-6-(2-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=CC=C1F IATKCZGRJQMHGD-UHFFFAOYSA-N 0.000 claims 1
- ROZAZEMSVYGULZ-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-6-(2-methoxyphenyl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=CC=C1OC ROZAZEMSVYGULZ-UHFFFAOYSA-N 0.000 claims 1
- KZWDCBZXCFBSAW-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-6-(3-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=CC(F)=C1 KZWDCBZXCFBSAW-UHFFFAOYSA-N 0.000 claims 1
- LIJZDASQNMTIQH-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-6-(3-fluoropyridin-4-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=NC=C1F LIJZDASQNMTIQH-UHFFFAOYSA-N 0.000 claims 1
- ICUSOCZQLLNDQV-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-6-(3-methoxyphenyl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=CC(OC)=C1 ICUSOCZQLLNDQV-UHFFFAOYSA-N 0.000 claims 1
- HQWNQRKAEYRJJL-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-6-(4-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=C(F)C=C1 HQWNQRKAEYRJJL-UHFFFAOYSA-N 0.000 claims 1
- XEPWZBYOJGUZML-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-6-(4-methoxyphenyl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C1=CC=C(OC)C=C1 XEPWZBYOJGUZML-UHFFFAOYSA-N 0.000 claims 1
- VJEUHYDFQNWESU-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)-6-(furan-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC)=NC(C)=C2C=C1C=1C=COC=1 VJEUHYDFQNWESU-UHFFFAOYSA-N 0.000 claims 1
- PZIGHMJLTJTNDH-UHFFFAOYSA-N 8-ethyl-2-(ethylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(=O)N(CC)C2=NC(NCC)=NC=C21 PZIGHMJLTJTNDH-UHFFFAOYSA-N 0.000 claims 1
- LGEIBBIEAFXCKB-UHFFFAOYSA-N 8-ethyl-2-[4-(4-ethylpiperazin-1-yl)anilino]-4-methyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(C=2C=CC=CC=2)C(=O)N2CC)C2=N1 LGEIBBIEAFXCKB-UHFFFAOYSA-N 0.000 claims 1
- RBZKDWACKHNKCT-UHFFFAOYSA-N 8-ethyl-2-[4-(4-ethylpiperazin-1-yl)anilino]-4-methyl-6-thiophen-2-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(C=2SC=CC=2)C(=O)N2CC)C2=N1 RBZKDWACKHNKCT-UHFFFAOYSA-N 0.000 claims 1
- XJNBXNJHYUUBDW-UHFFFAOYSA-N 8-ethyl-2-[4-(4-ethylpiperazin-1-yl)anilino]-6-(3-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(C=2C=C(F)C=CC=2)C(=O)N2CC)C2=N1 XJNBXNJHYUUBDW-UHFFFAOYSA-N 0.000 claims 1
- VQAMSLDFGLDEHZ-UHFFFAOYSA-N 8-ethyl-2-[4-(4-ethylpiperazin-1-yl)anilino]-6-(furan-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=NC(C)=C(C=C(C2=COC=C2)C(=O)N2CC)C2=N1 VQAMSLDFGLDEHZ-UHFFFAOYSA-N 0.000 claims 1
- WPQXBIFIGCHPPR-UHFFFAOYSA-N 8-ethyl-4-methyl-2-(methylamino)-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NC)=NC(C)=C2C=C1C1=CC=NN1 WPQXBIFIGCHPPR-UHFFFAOYSA-N 0.000 claims 1
- FFVRINRLHYFBDJ-UHFFFAOYSA-N 8-ethyl-4-methyl-2-[4-(2-morpholin-4-ylethoxy)anilino]-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(C=3C=CC=CC=3)C(=O)N(CC)C2=NC=1NC(C=C1)=CC=C1OCCN1CCOCC1 FFVRINRLHYFBDJ-UHFFFAOYSA-N 0.000 claims 1
- FXDLJQYGPGZDSZ-UHFFFAOYSA-N 8-ethyl-4-methyl-2-[4-(4-methylpiperazin-1-yl)anilino]-6-thiophen-2-ylpyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(C=3SC=CC=3)C(=O)N(CC)C2=NC=1NC(C=C1)=CC=C1N1CCN(C)CC1 FXDLJQYGPGZDSZ-UHFFFAOYSA-N 0.000 claims 1
- VZKDEUQOMRCYFB-UHFFFAOYSA-N 8-ethyl-4-methyl-6-(1h-pyrazol-5-yl)-2-(2,2,2-trifluoroethylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(NCC(F)(F)F)=NC(C)=C2C=C1C1=CC=NN1 VZKDEUQOMRCYFB-UHFFFAOYSA-N 0.000 claims 1
- UHRXZCZBKZUOOB-UHFFFAOYSA-N 8-ethyl-4-methyl-6-phenyl-2-[4-(2-piperidin-1-ylethoxy)anilino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(C)=C2C=C(C=3C=CC=CC=3)C(=O)N(CC)C2=NC=1NC(C=C1)=CC=C1OCCN1CCCCC1 UHRXZCZBKZUOOB-UHFFFAOYSA-N 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 101150073900 PTEN gene Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000009311 VIPoma Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
- JLVKONGOFKFMSG-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-(3-ethenyl-3-hydroxyazetidin-1-yl)methanone Chemical compound C1C(O)(C=C)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F JLVKONGOFKFMSG-UHFFFAOYSA-N 0.000 claims 1
- RWBREZLXOJSIET-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-(3-ethyl-3-hydroxyazetidin-1-yl)methanone Chemical compound C1C(CC)(O)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RWBREZLXOJSIET-UHFFFAOYSA-N 0.000 claims 1
- KDQMGKLTDPLARQ-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-(3-hydroxy-3-methylazetidin-1-yl)methanone Chemical compound C1C(C)(O)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F KDQMGKLTDPLARQ-UHFFFAOYSA-N 0.000 claims 1
- DQOGYBHEBMFZGQ-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-(3-hydroxy-3-prop-2-enylazetidin-1-yl)methanone Chemical compound C1C(O)(CC=C)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F DQOGYBHEBMFZGQ-UHFFFAOYSA-N 0.000 claims 1
- COACPTNNJAFVAN-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound C1C(O)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F COACPTNNJAFVAN-UHFFFAOYSA-N 0.000 claims 1
- DYULZSLYHAGCKA-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-(3-hydroxyiminoazetidin-1-yl)methanone Chemical compound C1C(=NO)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F DYULZSLYHAGCKA-UHFFFAOYSA-N 0.000 claims 1
- VELUNLAKLQWONH-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-(3-methoxyazetidin-1-yl)methanone Chemical compound C1C(OC)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F VELUNLAKLQWONH-UHFFFAOYSA-N 0.000 claims 1
- WCXUOAHSMZLHHJ-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[2-(hydroxymethyl)azetidin-1-yl]methanone Chemical compound OCC1CCN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F WCXUOAHSMZLHHJ-UHFFFAOYSA-N 0.000 claims 1
- KTWSVKCOTQHEKG-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-(1,2-dihydroxyethyl)-3-hydroxyazetidin-1-yl]methanone Chemical compound C1C(C(O)CO)(O)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F KTWSVKCOTQHEKG-UHFFFAOYSA-N 0.000 claims 1
- FHMBCSSWNHGFON-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-(hydroxymethyl)azetidin-1-yl]methanone Chemical compound C1C(CO)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F FHMBCSSWNHGFON-UHFFFAOYSA-N 0.000 claims 1
- HUUPFBKNECWODN-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-[(dimethylamino)methyl]-3-hydroxyazetidin-1-yl]methanone Chemical compound C1C(CN(C)C)(O)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F HUUPFBKNECWODN-UHFFFAOYSA-N 0.000 claims 1
- OQQZKLZIDXLDLJ-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-(hydroxymethyl)azetidin-1-yl]methanone Chemical compound C1C(CO)(O)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F OQQZKLZIDXLDLJ-UHFFFAOYSA-N 0.000 claims 1
- RSECRMOYVYYDGW-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-(pyrrolidin-1-ylmethyl)azetidin-1-yl]methanone Chemical compound C1N(C(=O)C=2C(=C(F)C(F)=CC=2)NC=2C(=CC(I)=CC=2)F)CC1(O)CN1CCCC1 RSECRMOYVYYDGW-UHFFFAOYSA-N 0.000 claims 1
- JMVZVVBBNYXKEV-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone Chemical compound C1C(O)(C(F)(F)F)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F JMVZVVBBNYXKEV-UHFFFAOYSA-N 0.000 claims 1
- BSMCAPRUBJMWDF-QGZVFWFLSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2r)-piperidin-2-yl]azetidin-1-yl]methanone Chemical compound C1C(O)([C@@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-QGZVFWFLSA-N 0.000 claims 1
- ROZUZKLWYFJFQI-UHFFFAOYSA-N [3-(1-aminoethyl)-3-hydroxyazetidin-1-yl]-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]methanone Chemical compound C1C(C(N)C)(O)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F ROZUZKLWYFJFQI-UHFFFAOYSA-N 0.000 claims 1
- GLTAPZSWBNABCW-UHFFFAOYSA-N [3-(aminomethyl)-3-hydroxyazetidin-1-yl]-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]methanone Chemical compound C1C(CN)(O)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F GLTAPZSWBNABCW-UHFFFAOYSA-N 0.000 claims 1
- LSGPROFVHFKBPK-UHFFFAOYSA-N [3-(butylamino)azetidin-1-yl]-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]methanone Chemical compound C1C(NCCCC)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F LSGPROFVHFKBPK-UHFFFAOYSA-N 0.000 claims 1
- ZGLBDNNACLJNLJ-UHFFFAOYSA-N [3-(diethylaminomethyl)-3-hydroxyazetidin-1-yl]-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]methanone Chemical compound C1C(CN(CC)CC)(O)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F ZGLBDNNACLJNLJ-UHFFFAOYSA-N 0.000 claims 1
- CVRVSPBYGJYKMS-UHFFFAOYSA-N [3-[bis(prop-2-enyl)amino]azetidin-1-yl]-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]methanone Chemical compound C=1C=C(I)C=C(F)C=1NC1=C(F)C(F)=CC=C1C(=O)N1CC(N(CC=C)CC=C)C1 CVRVSPBYGJYKMS-UHFFFAOYSA-N 0.000 claims 1
- LTRWLJURZZHUDX-UHFFFAOYSA-N [4-(2-fluoro-4-iodoanilino)thiophen-3-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound C1C(O)CN1C(=O)C1=CSC=C1NC1=CC=C(I)C=C1F LTRWLJURZZHUDX-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- YVSXASJEPXDDQH-UHFFFAOYSA-N azetidin-1-yl-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]methanone Chemical compound C=1C=C(I)C=C(F)C=1NC1=C(F)C(F)=CC=C1C(=O)N1CCC1 YVSXASJEPXDDQH-UHFFFAOYSA-N 0.000 claims 1
- KKCWBKUOPJMUQV-UHFFFAOYSA-N azetidine-2-carboxamide Chemical compound NC(=O)C1CCN1 KKCWBKUOPJMUQV-UHFFFAOYSA-N 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000004240 chinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 claims 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 claims 1
- OJEYDZBIAYMFFD-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1C[CH]CC1 OJEYDZBIAYMFFD-UHFFFAOYSA-N 0.000 claims 1
- BSEXNZMHLUMQKR-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1.NC(=O)C1CC1 BSEXNZMHLUMQKR-UHFFFAOYSA-N 0.000 claims 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000002009 diols Chemical class 0.000 claims 1
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 claims 1
- GOLHZPOXCLTFRB-UHFFFAOYSA-N furan-3-carboxamide Chemical compound NC(=O)C=1C=COC=1 GOLHZPOXCLTFRB-UHFFFAOYSA-N 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 claims 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 1
- GKFMAGUWGRNGIW-UHFFFAOYSA-N n-(1h-imidazol-5-yl)acetamide Chemical compound CC(=O)NC1=CN=CN1 GKFMAGUWGRNGIW-UHFFFAOYSA-N 0.000 claims 1
- SCPIEZMZYXGTJQ-UHFFFAOYSA-N n-(3-azidoquinoxalin-2-yl)benzenesulfonamide Chemical compound [N-]=[N+]=NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 SCPIEZMZYXGTJQ-UHFFFAOYSA-N 0.000 claims 1
- WDODZHUPOWPLLQ-UHFFFAOYSA-N n-(3-morpholin-4-ylquinoxalin-2-yl)benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1N1CCOCC1 WDODZHUPOWPLLQ-UHFFFAOYSA-N 0.000 claims 1
- GRJJUFYGWAHZDZ-UHFFFAOYSA-N n-(3-piperazin-1-ylquinoxalin-2-yl)benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1N1CCNCC1 GRJJUFYGWAHZDZ-UHFFFAOYSA-N 0.000 claims 1
- SBWFTBDLVKJJKG-UHFFFAOYSA-N n-[1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]azetidin-3-yl]-2-methylpropanamide Chemical compound C1C(NC(=O)C(C)C)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SBWFTBDLVKJJKG-UHFFFAOYSA-N 0.000 claims 1
- FVMSYKSCRZQSRY-UHFFFAOYSA-N n-[1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]azetidin-3-yl]-3,4-dihydroxybutanamide Chemical compound C1C(NC(=O)CC(O)CO)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F FVMSYKSCRZQSRY-UHFFFAOYSA-N 0.000 claims 1
- VFYTWFMPMFOXFU-UHFFFAOYSA-N n-[1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]azetidin-3-yl]acetamide Chemical compound C1C(NC(=O)C)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F VFYTWFMPMFOXFU-UHFFFAOYSA-N 0.000 claims 1
- NMDYHLPRZQJKGH-UHFFFAOYSA-N n-[1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]azetidin-3-yl]formamide Chemical compound C=1C=C(I)C=C(F)C=1NC1=C(F)C(F)=CC=C1C(=O)N1CC(NC=O)C1 NMDYHLPRZQJKGH-UHFFFAOYSA-N 0.000 claims 1
- JAUYYOYZXIPIHA-UHFFFAOYSA-N n-[1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]azetidin-3-yl]methanesulfonamide Chemical compound C1C(NS(=O)(=O)C)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F JAUYYOYZXIPIHA-UHFFFAOYSA-N 0.000 claims 1
- CZZYXOIATLGGMZ-UHFFFAOYSA-N n-[2-(3,5-dimethoxyanilino)pyrido[2,3-b]pyrazin-3-yl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=NC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 CZZYXOIATLGGMZ-UHFFFAOYSA-N 0.000 claims 1
- OIYTTYTXAPTUHJ-UHFFFAOYSA-N n-[3-(1,3-benzoxazol-4-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC=2C(=NC3=CC=CC=C3N=2)NC=2C=3N=COC=3C=CC=2)=C1 OIYTTYTXAPTUHJ-UHFFFAOYSA-N 0.000 claims 1
- DEPNUQFLYVAMOB-UHFFFAOYSA-N n-[3-(2,5-difluoroanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC=2C(=NC3=CC=CC=C3N=2)NC=2C(=CC=C(F)C=2)F)=C1 DEPNUQFLYVAMOB-UHFFFAOYSA-N 0.000 claims 1
- DXKNNTPDJCRGNF-UHFFFAOYSA-N n-[3-(2,5-dimethoxyanilino)quinoxalin-2-yl]-3-fluorobenzenesulfonamide Chemical compound COC1=CC=C(OC)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(F)C=CC=2)=C1 DXKNNTPDJCRGNF-UHFFFAOYSA-N 0.000 claims 1
- VPHLBZQFYIBTTD-UHFFFAOYSA-N n-[3-(2-bromo-5-methoxyanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC=C(Br)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 VPHLBZQFYIBTTD-UHFFFAOYSA-N 0.000 claims 1
- GYOHNAHELJEHOT-UHFFFAOYSA-N n-[3-(2-chloro-5-hydroxyanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound OC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 GYOHNAHELJEHOT-UHFFFAOYSA-N 0.000 claims 1
- GCSONEIXMFMYCW-UHFFFAOYSA-N n-[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]-3-cyanobenzenesulfonamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)C#N)=C1 GCSONEIXMFMYCW-UHFFFAOYSA-N 0.000 claims 1
- XPEBIAOZZKOSIA-UHFFFAOYSA-N n-[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 XPEBIAOZZKOSIA-UHFFFAOYSA-N 0.000 claims 1
- WEBLIBNQYKLNTD-UHFFFAOYSA-N n-[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC=CC=2)=C1 WEBLIBNQYKLNTD-UHFFFAOYSA-N 0.000 claims 1
- LDGVJARGUDCVOA-UHFFFAOYSA-N n-[3-(2-ethoxyanilino)quinoxalin-2-yl]-4-methylbenzenesulfonamide Chemical compound CCOC1=CC=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(C)C=C1 LDGVJARGUDCVOA-UHFFFAOYSA-N 0.000 claims 1
- KXPNDIRUTROICT-UHFFFAOYSA-N n-[3-(2-methoxy-5-methylanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 KXPNDIRUTROICT-UHFFFAOYSA-N 0.000 claims 1
- WJUCGMYIQVTQSD-UHFFFAOYSA-N n-[3-(3,4,5-trimethoxyanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC=CC=2)=C1 WJUCGMYIQVTQSD-UHFFFAOYSA-N 0.000 claims 1
- URKUUAHRXWDAAN-UHFFFAOYSA-N n-[3-(3,5-dihydroxyanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound OC1=CC(O)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 URKUUAHRXWDAAN-UHFFFAOYSA-N 0.000 claims 1
- JCNOSOHICFTNRK-UHFFFAOYSA-N n-[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]-1-phenylmethanesulfonamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)CC=2C=CC=CC=2)=C1 JCNOSOHICFTNRK-UHFFFAOYSA-N 0.000 claims 1
- GUHPJSBYYNQHHJ-UHFFFAOYSA-N n-[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]-3-fluorobenzenesulfonamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(F)C=CC=2)=C1 GUHPJSBYYNQHHJ-UHFFFAOYSA-N 0.000 claims 1
- IKCRYIPVXLGUJT-UHFFFAOYSA-N n-[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]-4-fluorobenzenesulfonamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC(F)=CC=2)=C1 IKCRYIPVXLGUJT-UHFFFAOYSA-N 0.000 claims 1
- VMYGQSPBYZPYPX-UHFFFAOYSA-N n-[3-(3-ethoxyanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound CCOC1=CC=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 VMYGQSPBYZPYPX-UHFFFAOYSA-N 0.000 claims 1
- CBMXAFMMKWIIFV-UHFFFAOYSA-N n-[3-(3-fluoro-5-methoxyanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC(F)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 CBMXAFMMKWIIFV-UHFFFAOYSA-N 0.000 claims 1
- XAXWSIMEPCDROA-UHFFFAOYSA-N n-[3-(3-hydroxy-2-methylanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound CC1=C(O)C=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 XAXWSIMEPCDROA-UHFFFAOYSA-N 0.000 claims 1
- FUHAMYWGXQNABX-UHFFFAOYSA-N n-[3-(3-methoxy-4-phenylanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound C=1C=C(C=2C=CC=CC=2)C(OC)=CC=1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 FUHAMYWGXQNABX-UHFFFAOYSA-N 0.000 claims 1
- ULIBNGRYXJYWPA-UHFFFAOYSA-N n-[3-(3-methoxy-5-nitroanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 ULIBNGRYXJYWPA-UHFFFAOYSA-N 0.000 claims 1
- YTBPNLPCKOAKOW-UHFFFAOYSA-N n-[3-(3-methoxyanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 YTBPNLPCKOAKOW-UHFFFAOYSA-N 0.000 claims 1
- MVSPBNACOLDOJC-UHFFFAOYSA-N n-[3-(3-phenylmethoxyanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC(C=1)=CC=CC=1OCC1=CC=CC=C1 MVSPBNACOLDOJC-UHFFFAOYSA-N 0.000 claims 1
- NJIIAXSMCZUYKN-UHFFFAOYSA-N n-[3-(4-aminoindol-1-yl)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound C1=CC=2C(N)=CC=CC=2N1C1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 NJIIAXSMCZUYKN-UHFFFAOYSA-N 0.000 claims 1
- HKBCAAYMYGRDMA-UHFFFAOYSA-N n-[3-(4-benzylpiperidin-1-yl)quinoxalin-2-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1N(CC1)CCC1CC1=CC=CC=C1 HKBCAAYMYGRDMA-UHFFFAOYSA-N 0.000 claims 1
- DVBCTPSEVZPJQD-UHFFFAOYSA-N n-[3-(4-chloro-3-methoxyanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC=CC=2)=C1 DVBCTPSEVZPJQD-UHFFFAOYSA-N 0.000 claims 1
- RZATXRWUEOTZNP-UHFFFAOYSA-N n-[3-(4-fluoro-3-methoxyanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC=CC=2)=C1 RZATXRWUEOTZNP-UHFFFAOYSA-N 0.000 claims 1
- WXNHKTZCPCASFP-UHFFFAOYSA-N n-[3-(4-morpholin-4-ylanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC(C=C1)=CC=C1N1CCOCC1 WXNHKTZCPCASFP-UHFFFAOYSA-N 0.000 claims 1
- WEHDECIZGVKNGT-UHFFFAOYSA-N n-[3-(5-chloro-2-methoxyanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound COC1=CC=C(Cl)C=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 WEHDECIZGVKNGT-UHFFFAOYSA-N 0.000 claims 1
- SNVIZTHFQQGRKD-UHFFFAOYSA-N n-[3-(5-methoxy-2-methylanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC=C(C)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 SNVIZTHFQQGRKD-UHFFFAOYSA-N 0.000 claims 1
- BIHIEEVWLKOHEM-UHFFFAOYSA-N n-[3-(5-methoxy-2-methylanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound COC1=CC=C(C)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC=CC=2)=C1 BIHIEEVWLKOHEM-UHFFFAOYSA-N 0.000 claims 1
- QKTUZKDUDCREOV-UHFFFAOYSA-N n-[3-(dimethylamino)quinoxalin-2-yl]benzenesulfonamide Chemical compound CN(C)C1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 QKTUZKDUDCREOV-UHFFFAOYSA-N 0.000 claims 1
- WPWUBFAQTDNQBZ-UHFFFAOYSA-N n-[3-[(2,2-difluoro-1,3-benzodioxol-4-yl)amino]quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC=2C(=NC3=CC=CC=C3N=2)NC=2C=3OC(F)(F)OC=3C=CC=2)=C1 WPWUBFAQTDNQBZ-UHFFFAOYSA-N 0.000 claims 1
- LMQJIZOVNCBGIL-UHFFFAOYSA-N n-[3-[(2-chloropyridin-3-yl)amino]quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC=2C(=NC3=CC=CC=C3N=2)NC=2C(=NC=CC=2)Cl)=C1 LMQJIZOVNCBGIL-UHFFFAOYSA-N 0.000 claims 1
- OQNSRJMGMBDXKR-UHFFFAOYSA-N n-[3-[(2-chloropyridin-4-yl)amino]quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC=2C(=NC3=CC=CC=C3N=2)NC=2C=C(Cl)N=CC=2)=C1 OQNSRJMGMBDXKR-UHFFFAOYSA-N 0.000 claims 1
- PHZVSEBQERVVMT-UHFFFAOYSA-N n-[3-[(2-methoxypyridin-3-yl)amino]quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound COC1=NC=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 PHZVSEBQERVVMT-UHFFFAOYSA-N 0.000 claims 1
- QCSZQQAFTXNGPI-UHFFFAOYSA-N n-[3-[(4-methoxy-6-oxo-1h-pyrimidin-2-yl)amino]quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC(O)=NC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=N1 QCSZQQAFTXNGPI-UHFFFAOYSA-N 0.000 claims 1
- KRBBTKUVPSUBFG-UHFFFAOYSA-N n-[3-[(4-methylpyridin-3-yl)amino]quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound CC1=CC=NC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 KRBBTKUVPSUBFG-UHFFFAOYSA-N 0.000 claims 1
- YSIYRYJKZDDDLR-UHFFFAOYSA-N n-[3-[(6-methoxyquinolin-8-yl)amino]quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound C=12N=CC=CC2=CC(OC)=CC=1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 YSIYRYJKZDDDLR-UHFFFAOYSA-N 0.000 claims 1
- WNVMFNDEVNZVAY-UHFFFAOYSA-N n-[3-[2-methoxy-5-(trifluoromethyl)anilino]quinoxalin-2-yl]benzenesulfonamide Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 WNVMFNDEVNZVAY-UHFFFAOYSA-N 0.000 claims 1
- MZGVTYMXPUMMLJ-UHFFFAOYSA-N n-[3-[3-(difluoromethoxy)anilino]quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC=2C(=NC3=CC=CC=C3N=2)NC=2C=C(OC(F)F)C=CC=2)=C1 MZGVTYMXPUMMLJ-UHFFFAOYSA-N 0.000 claims 1
- IIKQFZRBNPKMAF-UHFFFAOYSA-N n-[3-[3-methoxy-5-(trifluoromethyl)anilino]quinoxalin-2-yl]benzenesulfonamide Chemical compound FC(F)(F)C1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC=CC=2)=C1 IIKQFZRBNPKMAF-UHFFFAOYSA-N 0.000 claims 1
- USGUXOGTTSNAGH-UHFFFAOYSA-N n-[3-[4-(2-methoxyphenyl)anilino]quinoxalin-2-yl]benzenesulfonamide Chemical compound COC1=CC=CC=C1C(C=C1)=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 USGUXOGTTSNAGH-UHFFFAOYSA-N 0.000 claims 1
- XBNPXSPGCMUDHP-UHFFFAOYSA-N n-[3-[4-(9-oxofluorene-1-carbonyl)piperazin-1-yl]quinoxalin-2-yl]benzenesulfonamide Chemical compound C=1C=CC=2C3=CC=CC=C3C(=O)C=2C=1C(=O)N(CC1)CCN1C1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 XBNPXSPGCMUDHP-UHFFFAOYSA-N 0.000 claims 1
- SBMGXRMNOXPNMR-UHFFFAOYSA-N n-[3-[[3-[(3-nitrophenyl)sulfonylamino]quinoxalin-2-yl]amino]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 SBMGXRMNOXPNMR-UHFFFAOYSA-N 0.000 claims 1
- ARFKGONNPZNFOM-UHFFFAOYSA-N n-methoxybenzenesulfonamide Chemical compound CONS(=O)(=O)C1=CC=CC=C1 ARFKGONNPZNFOM-UHFFFAOYSA-N 0.000 claims 1
- ZFIFHAKCBWOSRN-UHFFFAOYSA-N naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=CC=CC2=C1 ZFIFHAKCBWOSRN-UHFFFAOYSA-N 0.000 claims 1
- SWBLLSQMOMPTMC-UHFFFAOYSA-N naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)N)=CC=C21 SWBLLSQMOMPTMC-UHFFFAOYSA-N 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- DVFGVGYKHMQZJC-UHFFFAOYSA-N pent-4-enamide Chemical compound NC(=O)CCC=C DVFGVGYKHMQZJC-UHFFFAOYSA-N 0.000 claims 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims 1
- MYOHNZJKOAODMX-UHFFFAOYSA-N phenyl n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=CC=CC=C1 MYOHNZJKOAODMX-UHFFFAOYSA-N 0.000 claims 1
- 210000004214 philadelphia chromosome Anatomy 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- XIMBESZRBTVIOD-UHFFFAOYSA-N piperidine-2-carboxamide Chemical compound NC(=O)C1CCCCN1 XIMBESZRBTVIOD-UHFFFAOYSA-N 0.000 claims 1
- CXWQAPHDSYDHBR-UHFFFAOYSA-N piperidine-4-carboxamide Chemical compound NC(=O)C1CCNCC1.NC(=O)C1CCNCC1 CXWQAPHDSYDHBR-UHFFFAOYSA-N 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 1
- GEBGCSXVYUDDPU-UHFFFAOYSA-N pyridazine-4-carboxamide Chemical compound NC(=O)C1=CC=NN=C1 GEBGCSXVYUDDPU-UHFFFAOYSA-N 0.000 claims 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 1
- QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 claims 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- CFJWHGXFDYSGDW-UHFFFAOYSA-N tert-butyl n-[1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]azetidin-3-yl]carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F CFJWHGXFDYSGDW-UHFFFAOYSA-N 0.000 claims 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 claims 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 claims 1
- DAUYIKBTMNZABP-UHFFFAOYSA-N thiophene-3-carboxamide Chemical compound NC(=O)C=1C=CSC=1 DAUYIKBTMNZABP-UHFFFAOYSA-N 0.000 claims 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 description 8
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83830706P | 2006-08-16 | 2006-08-16 | |
| PCT/US2007/018057 WO2008021389A2 (en) | 2006-08-16 | 2007-08-16 | Using pi3k and mek modulators in treatments of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013102030A Division JP2013151570A (ja) | 2006-08-16 | 2013-05-14 | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010500994A JP2010500994A (ja) | 2010-01-14 |
| JP2010500994A5 true JP2010500994A5 (enExample) | 2011-03-31 |
Family
ID=38819883
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524671A Pending JP2010500994A (ja) | 2006-08-16 | 2007-08-16 | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| JP2013102030A Withdrawn JP2013151570A (ja) | 2006-08-16 | 2013-05-14 | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| JP2014067502A Pending JP2014122243A (ja) | 2006-08-16 | 2014-03-28 | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| JP2016019549A Withdrawn JP2016074743A (ja) | 2006-08-16 | 2016-02-04 | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| JP2017194176A Pending JP2017226702A (ja) | 2006-08-16 | 2017-10-04 | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013102030A Withdrawn JP2013151570A (ja) | 2006-08-16 | 2013-05-14 | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| JP2014067502A Pending JP2014122243A (ja) | 2006-08-16 | 2014-03-28 | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| JP2016019549A Withdrawn JP2016074743A (ja) | 2006-08-16 | 2016-02-04 | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| JP2017194176A Pending JP2017226702A (ja) | 2006-08-16 | 2017-10-04 | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20100075947A1 (enExample) |
| EP (1) | EP2056829B9 (enExample) |
| JP (5) | JP2010500994A (enExample) |
| CN (2) | CN101528231A (enExample) |
| AT (1) | ATE539752T1 (enExample) |
| AU (1) | AU2007284562B2 (enExample) |
| CA (1) | CA2658725A1 (enExample) |
| WO (1) | WO2008021389A2 (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8044062B2 (en) * | 2005-10-07 | 2011-10-25 | Exelixis, Inc. | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha |
| DE602006021205D1 (de) * | 2005-10-07 | 2011-05-19 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| ES2513165T3 (es) * | 2005-10-07 | 2014-10-24 | Exelixis, Inc. | Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa |
| AU2013201011B2 (en) * | 2005-10-07 | 2016-04-21 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| JP2010500994A (ja) * | 2006-08-16 | 2010-01-14 | エグゼリクシス， インコーポレイテッド | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| GEP20115306B (enExample) | 2006-09-15 | 2011-10-10 | Pfizer Prod Inc | |
| JP5311673B2 (ja) * | 2006-12-14 | 2013-10-09 | エグゼリクシス， インコーポレイテッド | Ｍｅｋ阻害剤の使用方法 |
| JP5508027B2 (ja) | 2007-02-22 | 2014-05-28 | メルク セローノ ソシエテ アノニム | キノキサリン化合物及びその使用 |
| WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| UA100979C2 (ru) | 2007-04-10 | 2013-02-25 | Экселиксис, Инк. | Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака |
| CA2683784A1 (en) * | 2007-04-11 | 2008-10-23 | Exelixis, Inc. | Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
| NZ580009A (en) * | 2007-04-11 | 2012-06-29 | Exelixis Inc | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer |
| NZ579945A (en) * | 2007-04-11 | 2012-05-25 | Exelixis Inc | Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| WO2009139886A2 (en) * | 2008-05-14 | 2009-11-19 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Targeting an hiv-1 nef-host cell kinase complex |
| GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| US8476431B2 (en) * | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| PT2374802E (pt) * | 2008-11-10 | 2014-07-10 | Kyowa Hakko Kirin Co Ltd | Inibidor de produção de quinurenina |
| US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
| CA2772790C (en) | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| BR112012006968A2 (pt) * | 2009-09-28 | 2019-09-24 | Glaxosmithkline Llc | combinação |
| US20110086837A1 (en) * | 2009-10-12 | 2011-04-14 | Genentech, Inc. | Combinations of a pi3k inhibitor and a mek inhibitor |
| AR080151A1 (es) | 2010-02-09 | 2012-03-14 | Exelixis Inc | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia |
| MX340392B (es) | 2010-02-25 | 2016-07-06 | Dana Farber Cancer Inst Inc | Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf. |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| TWI642670B (zh) | 2010-09-14 | 2018-12-01 | 伊塞利克斯公司 | Ｐｉ３ｋ-德爾塔抑制劑以及其應用和生產方法 |
| DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
| US20130211076A1 (en) * | 2010-10-20 | 2013-08-15 | Merck Serono S.A. Geneva | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides |
| WO2012065057A2 (en) * | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| US20130231347A1 (en) * | 2010-11-19 | 2013-09-05 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment with braf inhibitor |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| CN102718750B (zh) * | 2011-03-31 | 2015-03-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含吖啶环的氨基吡啶类衍生物及其用途 |
| EP2758057B1 (en) | 2011-09-22 | 2017-05-31 | Exelixis, Inc. | Method for treating osteoporosis |
| PE20141794A1 (es) | 2011-11-01 | 2014-12-17 | Exelixis Inc | N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas |
| WO2013067306A1 (en) * | 2011-11-02 | 2013-05-10 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers |
| CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
| JP6166289B2 (ja) | 2012-03-14 | 2017-07-19 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリダジン |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| JP6300042B2 (ja) | 2012-10-12 | 2018-03-28 | エグゼリクシス， インコーポレイテッド | 癌の処置に使用するための化合物の製造方法 |
| CA2890238A1 (en) | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP2934572A4 (en) | 2012-12-20 | 2016-11-23 | Biomatrica Inc | FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS |
| CN105339001A (zh) | 2013-03-15 | 2016-02-17 | 基因泰克公司 | 治疗癌症和预防癌症耐药性的方法 |
| TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| PT3008062T (pt) | 2013-06-11 | 2017-06-07 | Bayer Pharma AG | Derivados de profármaco de triazolopiridinas substituídas |
| EP3007556B1 (en) | 2013-06-13 | 2020-05-20 | Biomatrica, INC. | Cell stabilization |
| HUE053654T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére |
| JP6661554B2 (ja) | 2014-06-10 | 2020-03-11 | バイオマトリカ，インク． | 周囲温度における血小板の安定化 |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| WO2016010662A1 (en) * | 2014-07-16 | 2016-01-21 | Development Center For Biotechnology | Quinoxaline compounds, method for preparing the same and use thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| JP6827048B2 (ja) | 2015-12-08 | 2021-02-10 | バイオマトリカ，インク． | 赤血球沈降速度の低下 |
| US10822299B2 (en) | 2016-05-26 | 2020-11-03 | The Regents Of The University Of California | Compounds and methods for hematopoietic regeneration |
| US11633415B2 (en) | 2017-03-31 | 2023-04-25 | The Broad Institute, Inc. | Compounds and methods useful for treating or preventing cancers |
| US11896591B2 (en) | 2017-05-22 | 2024-02-13 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using mitochondrial uncouplers |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CA3084491A1 (en) * | 2017-11-29 | 2019-06-06 | The Regents Of The University Of California | Compounds and methods for hematopoietic regeneration |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| ES2991427T3 (es) | 2018-05-04 | 2024-12-03 | Incyte Corp | Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas |
| JP7304896B2 (ja) * | 2018-05-21 | 2023-07-07 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 複素縮合ピリドン化合物及びｉｄｈ阻害剤としてのこれらの使用 |
| JP7546297B2 (ja) * | 2018-11-20 | 2024-09-06 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのチエニル－アニリン化合物 |
| CA3120351A1 (en) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers |
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| CA3120337A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| MA55148A (fr) * | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12521395B2 (en) | 2019-11-08 | 2026-01-13 | Nerviano Medical Sciences S.R.L. | Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| ES2836551A1 (es) * | 2020-08-11 | 2021-06-25 | Molik Candelo Holmes | Fármaco andreaquivi C34H34N6O6S |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN117897140A (zh) * | 2021-07-16 | 2024-04-16 | 塞拉特药物股份有限公司 | 用于制备脂质体制剂的方法 |
| EP4436570A4 (en) | 2021-11-23 | 2025-10-22 | Nflection Therapeutics Inc | FORMULATIONS OF PYRROLOPYRIDINE-ANILINE COMPOUNDS |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69839338T2 (de) | 1997-02-05 | 2008-07-10 | Warner-Lambert Company Llc | Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation |
| NZ501277A (en) * | 1997-07-01 | 2002-12-20 | Warner Lambert Co | -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
| BRPI0510560A (pt) * | 2004-05-04 | 2007-11-20 | Warner Lambert Co | pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos |
| TW200626610A (en) * | 2004-10-13 | 2006-08-01 | Wyeth Corp | Analogs of 17-hydroxywortmannin as PI3K inhibitors |
| MX2007004781A (es) * | 2004-10-20 | 2007-05-11 | Applied Research Systems | Derivados de 3-arilamino piridina. |
| WO2007023186A1 (en) | 2005-08-26 | 2007-03-01 | Laboratoires Serono S.A. | Pyrazine derivatives and use as pi3k inhibitors |
| DE602006021205D1 (de) * | 2005-10-07 | 2011-05-19 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| ES2513165T3 (es) | 2005-10-07 | 2014-10-24 | Exelixis, Inc. | Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa |
| US8044062B2 (en) | 2005-10-07 | 2011-10-25 | Exelixis, Inc. | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha |
| US8247408B2 (en) * | 2005-10-07 | 2012-08-21 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer |
| JP2010500994A (ja) | 2006-08-16 | 2010-01-14 | エグゼリクシス， インコーポレイテッド | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| JP5311673B2 (ja) * | 2006-12-14 | 2013-10-09 | エグゼリクシス， インコーポレイテッド | Ｍｅｋ阻害剤の使用方法 |
| UA100979C2 (ru) | 2007-04-10 | 2013-02-25 | Экселиксис, Инк. | Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака |
| NZ580009A (en) | 2007-04-11 | 2012-06-29 | Exelixis Inc | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer |
| NZ579945A (en) | 2007-04-11 | 2012-05-25 | Exelixis Inc | Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
| CA2683784A1 (en) | 2007-04-11 | 2008-10-23 | Exelixis, Inc. | Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
| AR073524A1 (es) | 2008-09-30 | 2010-11-10 | Exelixis Inc | Piridopirimidinonas inhibidores de pi3k a y m tor |
| AR080151A1 (es) | 2010-02-09 | 2012-03-14 | Exelixis Inc | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia |
-
2007
- 2007-08-16 JP JP2009524671A patent/JP2010500994A/ja active Pending
- 2007-08-16 CN CNA200780038496XA patent/CN101528231A/zh not_active Withdrawn
- 2007-08-16 US US12/373,257 patent/US20100075947A1/en not_active Abandoned
- 2007-08-16 CN CN201510204883.2A patent/CN104784695A/zh active Pending
- 2007-08-16 EP EP07811344A patent/EP2056829B9/en active Active
- 2007-08-16 AT AT07811344T patent/ATE539752T1/de active
- 2007-08-16 AU AU2007284562A patent/AU2007284562B2/en not_active Ceased
- 2007-08-16 WO PCT/US2007/018057 patent/WO2008021389A2/en not_active Ceased
- 2007-08-16 CA CA002658725A patent/CA2658725A1/en not_active Abandoned
-
2012
- 2012-08-07 US US13/568,649 patent/US8642584B2/en active Active
-
2013
- 2013-05-14 JP JP2013102030A patent/JP2013151570A/ja not_active Withdrawn
- 2013-12-07 US US14/099,939 patent/US20140100215A1/en not_active Abandoned
-
2014
- 2014-03-28 JP JP2014067502A patent/JP2014122243A/ja active Pending
-
2016
- 2016-02-04 JP JP2016019549A patent/JP2016074743A/ja not_active Withdrawn
-
2017
- 2017-10-04 JP JP2017194176A patent/JP2017226702A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500994A5 (enExample) | ||
| EP2056829B9 (en) | Using pi3k and mek modulators in treatments of cancer | |
| ES2513165T3 (es) | Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa | |
| JP5726515B2 (ja) | Ｐｉ３ｋ−アルファのキナゾリン阻害剤を用いた阻害による治療方法 | |
| KR101985050B1 (ko) | 피라진카르복사미드 화합물 | |
| CN104507926B (zh) | 丝氨酸/苏氨酸激酶抑制剂 | |
| CN105848723B (zh) | 丝氨酸/苏氨酸激酶抑制剂 | |
| CN105980387A (zh) | 丝氨酸/苏氨酸激酶抑制剂 | |
| JP2017508763A5 (enExample) | ||
| JP2005524668A (ja) | ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用 | |
| CN103261165B (zh) | 胰高血糖素受体调节剂 | |
| HK1130438B (en) | Using pi3k and mek modulators in treatments of cancer | |
| HK1225735B (zh) | 絲氨酸/蘇氨酸激酶抑制劑 | |
| HK1187907A (en) | Glucagon receptor modulators |